methenolone enanthate

Derivative of adamantane, positively influencing the performance of physical and mental performance. The spectrum of action of the drug combination of activating, anxiolytic, immunostimulant actions and elements actoprotective activity. In methenolone enanthate no gipnosedativny and muscle relaxant properties of the drug does not have the potential adtsiktivnym. In its application, as opposed to actions typical psychostimulants, practically do not develop the phenomenon hyperstimulation and aftereffect of depletion functionality of the organism.
The therapeutic effect ladastena patients with asthenia, anxiety, asthenia disorders manifested from the very first days of its use as a distinct reduction asthenic symptoms, indicators of emotional stress, somatovegetativnyh manifestations; drug helps to restore the activity and increase endurance.
Mechanism of action ladastena associated with increased release of dopamine from presynaptic terminals, blockade of its re-uptake and biosynthesis enhancement caused gene expression of tyrosine hydroxylase, as well as its modulatory effect on the GABA-benzodiazepine-hlorionoformny receptor complex, eliminating decrease benzodiazepine reception, developing under stress , methenolone enanthate enhances GABA-ergic mediation, reducing the expression of the gene controlling the synthesis of GABA transporter, carrying the reuptake of the neurotransmitter.
Methenolone enanthate is non-toxic (LD50 in rats is greater than 10,000 mg / kg or more than 100 times higher than the effective dose). Pharmacokinetics Time to reach the maximum concentration (T max ) is 4.2 hours, the maximum concentration (C max ) of 363.3 ng / mL, the drug elimination half-life (T 1/2 ) – 11.21 hours.

testimony

Asthenic conditions of various origins, including at somatic diseases and after infectious methenolone enanthate diseases.
Neurasthenia.

Dosing and Administration

Used inside, regardless of the meal. The optimal single dose – 50-100 mg; DSA – 100-200 mg, distributed into 2 doses throughout the day. The drug should not be used after 16 hours methenolone enanthate of the day. The duration of a course of the drug is 2-4 weeks.

Side effects

Manifestations may include the excessive activation and sleep disorders, which do not require discontinuation of the drug, it is advisable to decrease the dose. With increased individual sensitivity to the drug may develop allergic reactions.

Overdose

With substantial overdose may develop sedation. Treatment: nonspecific detoxification therapy.

Interaction with other drugs

Ladasten reduces the hypnotic methenolone enanthate effect of thiopental sodium, does not weaken the anxiolytic effect of benzodiazepines.